Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $1.88 USD
Change Today +0.01 / 0.53%
Volume 312.8K
CLBS On Other Exchanges
As of 8:10 PM 06/29/15 All times are local (Market data is delayed by at least 15 minutes).

caladrius biosciences inc (CLBS) Snapshot

Previous Close
Day High
Day Low
52 Week High
11/17/14 - $7.22
52 Week Low
06/29/15 - $1.80
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

caladrius biosciences inc (CLBS) Related Businessweek News

No Related Businessweek News Found

caladrius biosciences inc (CLBS) Details

Caladrius Biosciences, Inc., a clinical-stage biopharmaceutical company, develops cell based therapeutics in the United States. It is developing NBS20, a targeted cancer immunotherapy product that is in Phase III clinical trials for the treatment of metastatic melanoma; NBS10, a ischemic repair product that is in Phase II clinical trial to preserve heart muscle function following an acute myocardial infarction; and NBS03D, an immune modulation product that is in Phase II clinical trials for the treatment of type 1 diabetes. The company, through its subsidiary, Progenitor Cell Therapy, offers process development and clinical manufacturing services. It is also involved in oncology, cord blood, and adult stem cell processing and banking activities; and the provision of clinical services. The company was formerly known as NeoStem, Inc. and changed its name to Caladrius Biosciences, Inc. in June 2015. Caladrius Biosciences, Inc. was founded in 1980 and is headquartered in New York, New York.

182 Employees
Last Reported Date: 03/2/15
Founded in 1980

caladrius biosciences inc (CLBS) Top Compensated Officers

Chief Technology Officer, Chief Scientific Of...
Total Annual Compensation: $418.6K
Chief Medical Officer and Senior Vice Preside...
Total Annual Compensation: $445.2K
Compensation as of Fiscal Year 2014.

caladrius biosciences inc (CLBS) Key Developments

Caladrius Biosciences, Inc. Announces First Patient Dosed in Phase 3 Immunotherapy Trial for Melanoma

Caladrius Biosciences, Inc. announced the dosing of the first patient in the Intus Phase 3 clinical trial. The Intus trial is investigating the efficacy of the company's patient-specific targeted cancer immunotherapy candidate CLBS20 (also known as NBS20). The trial is studying CLBS20 in patients with stage III recurrent or stage IV metastatic melanoma. The patient was dosed (with either CLBS20 or control, in accordance with the randomized, double-blind design of the study) at the clinical trial site at Thomas Jefferson University Hospital in Philadelphia, Pennsylvania. The announcement comes on the heels of a $17.7 million grant from the California Institute for Regenerative Medicine awarded to help fund the trial. The Intus trial is based on consistent, compelling results from two Phase 2 trials in identical patient populations evaluating the therapeutic vaccine that has become CLBS20. The more recent of the two trials was a randomized trial comparing CLBS20 to injections of autologous irradiated (inactivated) tumor cells in 42 patients. At two years, survival was 72% compared to 31% for control patients, which was consistent with the previous Phase 2 trial's findings in which CLBS20 demonstrated 73% two-year survival in 54 patients, with a median survival of five years. Treatments were well-tolerated; the most common side effects were mild to moderate local injections site reactions.

Caladrius Biosciences, Inc. Announces Research Collaboration with the University of Southern California and California Institute of Technology

Caladrius Biosciences, Inc. announced that it has entered into a material transfer agreement with the University of Southern California and the California Institute of Technology, concerning next-generation strategies for its core cancer technology. This research collaboration will build on Caladrius' highly successful manufacturing protocol for its lead cancer program, CLBS20 (aka NBS20), by exploring techniques to further enhance the isolation of cancer initiating cells with the goal of increasing the number of cancer patients that might benefit from treatment. CLBS20 is the subject of a Phase 3 clinical trial investigating its efficacy in the treatment of late-stage melanoma, the Intus Study. The trial has been granted a Special Protocol Assessment by the US Food and Drug Administration (FDA) and the CLBS20 development program has been granted Orphan Drug and Fast Track designations by FDA. Randomization of the first patient in the Intus trial occurred in April 2015. Advanced melanoma is exceedingly difficult to treat, with a five-year survival rate of approximately 15%. There are 20,000 estimated new cases, and an estimated 10,000 deaths, from metastatic melanoma each year in the United States. The US melanoma market is approximately $1 billion per year, which is predominantly spent to treat metastatic melanoma. The platform on which CLBS20 is based is potentially applicable across multiple solid tumor types, including lung, colon and ovarian cancer, hepatocellular carcinoma and glioblastoma multiforme. CLBS20 uses the patient's own immune cells and tumor-initiating cells to create an immunotherapy therapeutic vaccine. It is unique in targeting these cancer- or tumor-initiating cells; other therapies, which target different tumor cells, may treat existing cancer but may not be as likely to prevent tumor recurrence.

Caladrius Biosciences, Inc. Presents at BIO International Convention 2015, Jun-16-2015 10:30 AM

Caladrius Biosciences, Inc. Presents at BIO International Convention 2015, Jun-16-2015 10:30 AM. Venue: Pennsylvania Convention Center, Philadelphia, Pennsylvania, United States. Speakers: Robert S. Vaters, President, Chief Financial Officer, Secretary and Director.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CLBS:US $1.88 USD +0.01

CLBS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Athersys Inc $1.18 USD -0.08
Cesca Therapeutics Inc $0.84 USD +0.0546
Cytori Therapeutics Inc $0.56 USD -0.03
International Stem Cell Corp $0.04 USD -0.0023
StemCells Inc $0.50 USD -0.084
View Industry Companies

Industry Analysis


Industry Average

Valuation CLBS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 4.1x
Price/Book 1.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales 3.6x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CALADRIUS BIOSCIENCES INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at